Difference between revisions of "Vascular sarcoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 18: Line 18:
 
==[https://www.nccn.org/ NCCN]==
 
==[https://www.nccn.org/ NCCN]==
 
*[https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf NCCN Guidelines - Soft Tissue Sarcoma]
 
*[https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf NCCN Guidelines - Soft Tissue Sarcoma]
−
=Angiosarcoma, all lines of therapy=
 
−
==Bevacizumab monotherapy {{#subobject:3c01a5|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:c663b6|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 25%" |Study
 
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1093/annonc/mds237 Agulnik et al. 2013 (NU 04S1)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1
 
−
'''21-day cycles'''
 
−
</div></div>
 
−
===References===
 
−
#'''NU 04S1:''' Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. [https://doi.org/10.1093/annonc/mds237 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22910841/ PubMed] NCT00288015
 
−
==Paclitaxel monotherapy {{#subobject:6e2606|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:ebf64d|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 25%" |Study
 
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1200/jco.2008.17.3146 Penel et al. 2008 (ANGIOTAX)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15
 
−
====Supportive therapy====
 
−
*[[Dexamethasone (Decadron)]] 8 mg IV once per day on days 1, 8, 15, prior to [[Paclitaxel (Taxol)]]
 
−
*[[Cimetidine (Tagamet)]] 200 mg IV once per day on days 1, 8, 15, prior to [[Paclitaxel (Taxol)]]
 
−
*[[Dexchlorpheniramine (Polaramine)]] 5 mg IV once per day on days 1, 8, 15, prior to [[Paclitaxel (Taxol)]]
 
−
*"Standard [[:Category:Emesis_prevention|antiemetics]] (mainly [[Metoclopramide (Reglan)]]) were prescribed as clinically indicated by the treating physician"
 
−
'''28-day cycle for 6 cycles'''
 
−
</div></div>
 
−
===References===
 
−
#'''ANGIOTAX:''' Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. [https://doi.org/10.1200/jco.2008.17.3146 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18809609 PubMed]
 
−
==Pazopanib monotherapy {{#subobject:6hg776|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:1ug64d|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Dates of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8972152/ Jones et al. 2022 (TAPPAS)]
 
−
|2017-2019
 
−
| style="background-color:#1a9851" |Phase 3 (C)
 
−
|[[#Pazopanib_.26_Carotuximab_77|Pazopanib & Carotuximab]]
 
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS
 
−
|-
 
−
|}
 
−
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Pazopanib (Votrient)]] 800 mg PO once per day
 
−
'''Continued indefinitely'''
 
−
</div></div>
 
−
===References===
 
−
#'''TAPPAS:''' Jones RL, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):740-747. [https://doi.org/10.1001/jamaoncol.2021.3547 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8972152/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35357396/ PubMed] NCT02979899
 
 
=Hemangioendothelioma, all lines of therapy=
 
=Hemangioendothelioma, all lines of therapy=
 
=Hemangiopericytoma (solitary fibrous tumor), all lines of therapy=
 
=Hemangiopericytoma (solitary fibrous tumor), all lines of therapy=

Revision as of 23:20, 26 April 2023

Back to Top

Section editor transclusions

0 regimens on this page
0 variants on this page

Note: this page contains regimens for several subtypes of vascular sarcoma. The following links will take you to disease-specific pages:


Guidelines

ESMO

NCCN

Hemangioendothelioma, all lines of therapy

Hemangiopericytoma (solitary fibrous tumor), all lines of therapy

Retrieved from "https://hemonc.org/w/index.php?title=Vascular_sarcoma&oldid=68820"